Gemmer Asset Management LLC Has $406,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Gemmer Asset Management LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,627 shares of the biopharmaceutical company’s stock after selling 123 shares during the period. Gemmer Asset Management LLC’s holdings in Gilead Sciences were worth $406,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in GILD. Norges Bank bought a new position in Gilead Sciences during the 4th quarter worth $1,789,254,000. FMR LLC increased its position in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the period. GAMMA Investing LLC increased its position in Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock worth $285,761,000 after buying an additional 2,532,070 shares during the period. Northern Trust Corp increased its position in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after buying an additional 2,458,954 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Gilead Sciences during the 4th quarter worth $207,340,000. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the sale, the chief financial officer now directly owns 168,174 shares in the company, valued at $17,893,713.60. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,929 shares of company stock worth $6,748,980. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Royal Bank of Canada raised their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 12th. Piper Sandler raised their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $110.55.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $112.46 on Friday. The stock has a market cap of $139.89 billion, a PE ratio of 303.95, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business’s 50-day moving average price is $105.39 and its two-hundred day moving average price is $101.47. Gilead Sciences, Inc. has a 12-month low of $62.69 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.32) earnings per share. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.81%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.